High Tumor Stroma Proportion is a Worse Prognostic Factor in Colorectal Cancer
Overview
Affiliations
High stroma proportion appears to be a very important prognostic factor in esophageal and breast cancer. Previous researches have shown that it might have a similar effect on colorectal cancer. The aim of this study was to determine whether tumor stroma proportion influenced patient survival. This retrospective study included 236 patients with colorectal cancer having undergone surgery in 2006 and 2007 at Osijek University Hospital Center. Location with the highest stroma proportion at the site of deepest tumor invasion was determined. Patients were divided into the groups with high stroma proportion (>50%) and low stroma proportion (≤50%). Stroma proportion showed a statistically significant correlation with tumor stage. Kaplan-Meier survival curves yielded a statistically significant difference in patient overall survival (Cox ph model p=0.016) and progression-free survival (Cox ph model, p=0.0188) according to stroma proportion. Study results showed a statistically significantly shorter overall survival and progression-free survival in patients with high stroma proportion.
QUALITY OF LIFE OF OSTOMATES - A QUALITATIVE STUDY.
Vasiljev V, Haring M, Juraga D, Rovis D, Racz A, Rukavina T Acta Clin Croat. 2025; 63(1):29-35.
PMID: 39959334 PMC: 11827400. DOI: 10.20471/acc.2024.63.01.4.
Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer.
Lou E, Clemente V, Grube M, Svedbom A, Nelson A, Blome F JAMA Netw Open. 2024; 7(2):e240407.
PMID: 38411963 PMC: 10900967. DOI: 10.1001/jamanetworkopen.2024.0407.
van Wagensveld L, Walker C, Hahn K, Sanders J, Kruitwagen R, van der Aa M Res Sq. 2023; .
PMID: 38014112 PMC: 10680933. DOI: 10.21203/rs.3.rs-3511087/v1.
Prognostic Value of Tumor-Stroma Ratio in Rectal Cancer: A Systematic Review and Meta-analysis.
Zhu Y, Jin Z, Qian Y, Shen Y, Wang Z Front Oncol. 2021; 11:685570.
PMID: 34123856 PMC: 8187802. DOI: 10.3389/fonc.2021.685570.
Lou E, Vogel R, Hoostal S, Klein M, Linden M, Teoh D JAMA Oncol. 2019; 5(8):1222-1224.
PMID: 31152668 PMC: 6547254. DOI: 10.1001/jamaoncol.2019.1943.